Few Years Later

The US Food and Drug Administration has given 23andMe authorization to market its direct-to-consumer health risk tests, as GenomeWeb has reported. The company will now offer 10 health risk tests, including ones for Parkinson's disease, late-onset Alzheimer's disease, and celiac disease, it adds.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.